Aiga Ua ou maua le DS8201A

Ua ou maua le DS8201A

Faʻamatalaga puʻupuʻu:

DS-8201a, also known as trastuzumab deruxtecan (T-DXd), is an antibody-drug conjugate (ADC) designed for the treatment of HER2-positive cancers. It combines a HER2-targeting monoclonal antibody (similar to trastuzumab) with a potent topoisomerase I inhibitor (deruxtecan) as the cytotoxic payload. The drug delivers chemotherapy directly to cancer cells expressing HER2, improving efficacy while limiting damage to normal cells.

Faʻafesoʻotaʻi nei Faʻaopopo i le faʻatauga taʻavale

Faamatalaga auiliiliga

Oloa Tags

Oloa Paleni DS - 8201A, o loʻo iloa foi o Rastozumab Deruxtecan (T - DXD), o se antibody - vailaʻau oona. E tuʻufaʻatasia le HE2 - Faʻamoemoega Monoclonal Antibody (tutusa ma Trastuzumab) ma se malosi o le faʻamalositino o le Cytotoroncy (Deruxtecan O le vailaʻau o loʻo tuʻuina atu le chemotherapy saʻo i le kanesa sela faʻaalia ai her2, faʻalelei lelei pe a faʻatapulaʻaina le faʻaleagaina o sela masani.

Vaega:
Tagata cathepsin
Aitema leai.:
015200.02
Lautele tele:
200oul, 2mg / ml
Tisu:
N / a
Ituaiga:
N / a
Taaloga tuutuuga ma Felauaiga:
Teu i - 70 ° C. Mamago aisa.